Katie Olson Anderson

USPTO Granted Patents = 38 (Patent Applications = 11)

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 8.7

ph-index = 10

Forward Citations = 202(Granted Patents)

Company Filing History:

28 out of 98

Alderbio Holdings LLC

Alder Biopharmaceuticals, Inc.

patents

Years Active: 2015-2025

Loading Chart...

38 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12428475 - Humanized anti-ACTH antibodies and use thereof (2025-09-30),

2. 12351627 - Anti-ACTH antibodies and use thereof (2025-07-08),

3. 11827700 - Treatment or prevention of diseases and disorders associated with cells that express IL-6 with Anti-IL-6 antibodies (2023-11-28),

4. 11427631 - Anti-ACTH antibodies and use thereof (2022-08-30),

5. 11117960 - Humanized anti-ACTH antibodies and use thereof (2021-09-14),

6. 11111289 - Anti-CGRP compositions and use thereof (2021-09-07),

7. 10913794 - Antibodies to IL-6 and use thereof (2021-02-09),

8. 10800841 - Methods of treating autoimmunity using specific anti-IL-6 antibodies (2020-10-13),

9. 10759853 - Antibodies to IL-6 and use thereof (2020-09-01),

10. 10550180 - Anti-ACTH antibodies and use thereof (2020-02-04),

11. 10544214 - Humanized anti-ACTH antibodies and use thereof (2020-01-28),

12. 10533048 - Anti-CGRP compositions and use thereof (2020-01-14),

13. 10391169 - Method of treating allergic asthma with antibodies to IL-6 (2019-08-27),

14. 10344086 - Antibodies to IL-6 and use thereof (2019-07-09),

15. 10259885 - Anti-PCSK9 antibodies and use thereof (2019-04-16),

Title: Katie Olson Anderson: Innovating in Antibody Therapeutics

Introduction

Katie Olson Anderson, based in Kirkland, WA, is a distinguished inventor with a remarkable portfolio of 36 patents. Her innovations primarily focus on the development of antibodies used in the treatment and prevention of diseases linked to interleukin-6 (IL-6) and adrenocorticotropic hormone (ACTH).

Latest Patents

Among her latest contributions are two significant patents: the first addresses the treatment or prevention of diseases associated with cells that express IL-6 using anti-IL-6 antibodies. This invention outlines the creation of antibodies and their fragments, humanized versions, and conjugates designed to bind IL-6, effectively inhibiting its biological effects related to various disorders. The second patent is focused on anti-ACTH antibodies, detailing their use in diagnosing and treating a range of health conditions, including Cushing's Disease, Parkinson's Disease, obesity, and cognitive dysfunction, among others. These innovative approaches highlight her dedication to advancing therapeutic options in the medical field.

Career Highlights

Katie has made significant strides in her career, contributing her expertise at Alderbio Holdings LLC and Vitaeris Inc. Her work within these organizations has been pivotal in the research and development of antibody-based therapies.

Collaborations

Throughout her career, Katie has collaborated with notable professionals such as Leon F. Garcia-Martinez and Benjamin H. Dutzar. These partnerships have strengthened her research outcomes and broadened the impact of her innovations within the scientific community.

Conclusion

Katie Olson Anderson is not only an influential inventor but also a key player in the evolution of antibody therapeutics. Her pioneering patents are essential in the ongoing battle against various diseases, emphasizing her commitment to improving patient health outcomes through innovative solutions.

This text is generated by artificial intelligence and may not be accurate.